| Old Articles: <Older 6371-6380 Newer> |
|---|
 |
The Motley Fool
June 4, 2010
Luke Timmerman |
Amgen Gets FDA Approval and SonoSite Has a New Frontier Quite a few Seattle biotechies are quietly gearing up for the always-important American Society of Clinical Oncology meeting from June 4 to 8 in Chicago. Here's some of the big headlines.   |
The Motley Fool
June 4, 2010
Jim Mueller |
The Changing Face of Abbott Abbott Labs' shift in revenue sources has been a boon over the last five years. |
The Motley Fool
June 4, 2010
Brian Richards |
Intuitive Surgical: Strengths, Weaknesses, Opportunities, Threats A look inside the business of the da Vinci robot maker. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
June 4, 2010
Brian Orelli |
This Cancer Drug's on a Roll Novartis' Afinitor scores another win. |
InternetNews
June 3, 2010 |
UofL Web Site Exposes Patients' Personal Info A doctor at the University of Louisville Hospital set up an internal Web site and data base to track and monitor kidney dialysis patients. The problem is the site wasn't password protected. |
The Motley Fool
June 3, 2010
Brian Orelli |
The Dragon That Cost Investors Millions The Securities and Exchange Commission filed a complaint against Elizabeth Dragon, the company's former Senior Vice President of Research and Development. |
The Motley Fool
June 3, 2010
Brian Orelli |
When All Else Fails, Sue Your Competitors Biogen thinks its patent covers its competitors' drugs in addition to Avonex and has filed a lawsuit demanding royalties from its competitors. |
The Motley Fool
June 2, 2010
Brian Orelli |
Take Your Low Margins and Shove 'Em In an effort to help lower its budget problems, Greece told drugmakers it was slashing prices of drugs, take it or leave it. Novo Nordisk chose "leave it." |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
| <Older 6371-6380 Newer> Return to current articles. |
